Cellular mechanisms for trazodone-induced cardiotoxicity

Human and Experimental Toxicology

Volumn 35, Issue 5, 2016, Pages 501-510

  Lee, S ^a   Lee, H A ^a,b   Kim, S J ^b   Kim, K S ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

action potentials; cardiotoxicity; human ether a go go related gene (hERG); ion channels; Selective 5 HT2 receptor antagonists and reuptake inhibitors (SARIs); trazodone

Indexed keywords

ION CHANNEL; TRAZODONE; ANTIDEPRESSANT AGENT; KCNE1 PROTEIN, HUMAN; KCNH2 PROTEIN, HUMAN; KCNQ1 PROTEIN, HUMAN; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KCNQ1; SEROTONIN UPTAKE INHIBITOR; VOLTAGE GATED POTASSIUM CHANNEL;

ACTION POTENTIAL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CURRENT CLAMP TECHNIQUE; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEK293 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MAXIMUM DIASTOLIC POTENTIAL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; QT PROLONGATION; WAVEFORM; WHOLE CELL PATCH CLAMP; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE CELL; CELL CULTURE TECHNIQUE; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATCH CLAMP TECHNIQUE;

ACTION POTENTIALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CARDIOTOXICITY; CELL CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ERG1 POTASSIUM CHANNEL; HEK293 CELLS; HUMANS; KCNQ1 POTASSIUM CHANNEL; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, VOLTAGE-GATED; SEROTONIN UPTAKE INHIBITORS; TRANSFECTION; TRAZODONE;

EID: 84964741404     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327115595683     Document Type: Article

References (46)

1. Nicholson A, Kuper H, Hemingway H,. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006; 27: 2763-2774.
2. Roose SP, Miyazaki M,. Pharmacologic treatment of depression in patients with heart disease. Psychosom med 2005; 67 (Suppl 1): S54-S57.
3. Jiang W, Davidson JR,. Antidepressant therapy in patients with ischemic heart disease. Am Heart J 2005; 150: 871-881.
4. Whooley MA, de Jonge P, Vittinghoff E, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008; 300: 2379-2388.
5. Elderon L, Whooley MA,. Depression and cardiovascular disease. Prog Cardiovas Dis 2013; 55: 511-523.
6. Coupland N, Wilson S, Nutt D,. Antidepressant drugs and the cardiovascular system: a comparison of tricylics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol (Oxford, England) 1997; 11: 83-92.
7. Glassman AH., Introduction. Optimizing clinical use of SSRIS: theory and practice. J Clin Psychiatry 1998; 59 (Suppl 15): 3.
8. Glassman AH,. Cardiovascular effects of antidepressant drugs: updated. J Clin Psychiatry 1998; 59 (Suppl 15): 13-18.
9. Glassman AH,. Cardiovascular effects of antidepressant drugs: updated. Int Clin Psychopharmacol 1998; 13 (Suppl 5): S25-S30.
10. Owens MJ, Ieni JR, Knight DL, et al. The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci 1995; 57: Pl373-Pl380.
11. Schatzberg AF,. New indications for antidepressants. J Clin Psychiatry 2000; 61 (Suppl 11): 9-17.
12. Eison AS, Eison MS, Torrente JR, et al. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull 1990; 26: 311-315.
13. Miura N, Saito T, Taira T, et al. Risk factors for qt prolongation associated with acute psychotropic drug overdose. Am J Emerg Med 2015; 33: 142-149.
14. Zitron E, Kiesecker C, Scholz E, et al. Inhibition of cardiac herg potassium channels by the atypical antidepressant trazodone. Naunyn-Schmiedeberg's Arch Pharmacol 2004; 370: 146-156.
15. Tarantino P, Appleton N, Lansdell K,. Effect of trazodone on herg channel current and qt-interval. Eur J Pharmacol 2005; 510: 75-85.
16. + current (i(to)) by antidepressant drugs. J Cardiovas Pharmacol 1998; 32: 527-534.
17. Chae YJ, Choi JS, Hahn SJ,. Inhibition of kv4.3 potassium channels by trazodone. Naunyn-Schmiedeberg's Arch Pharmacol 2013; 386: 711-719.
18. Aronson MD, Hafez H,. A case of trazodone-induced ventricular tachycardia. J Clin Psychiatry 1986; 47: 388-389.
19. Winkler D, Ortner R, Pjrek E, et al. Trazodone-induced cardiac arrhythmias: a report of two cases. Hum Psychopharmacol 2006; 21: 61-62.
20. Service JA, Waring WS,. Qt prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Philadelphia, Pa.) 2008; 46: 71-73.
21. de Meester A, Carbutti G, Gabriel L, et al. Fatal overdose with trazodone: case report and literature review. Acta Clin Belg 2001; 56: 258-261.
22. Katchman AN, Koerner J, Tosaka T, et al. Comparative evaluation of herg currents and qt intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Therapeut 2006; 316: 1098-1106.
23. Goldenberg I, Moss AJ,. Long qt syndrome. J Am Coll Cardiol 2008; 51: 2291-2300.
24. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: Herg mutations cause long qt syndrome. Cell 1995; 80: 795-803.
25. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: Kvlqt1 mutations cause cardiac arrhythmias. Nat Gen 1996; 12: 17-23.
26. Wang Q, Shen J, Splawski I, et al. Scn5a mutations associated with an inherited cardiac arrhythmia, long qt syndrome. Cell 1995; 80: 805-811.
27. Cohen JD, Babiarz JE, Abrams RM, et al. Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicol Appl Pharmacol 2011; 257: 74-83.
28. Xi B, Wang T, Li N, et al. Functional cardiotoxicity profiling and screening using the xcelligence rtca cardio system. J Lab Autom 2011; 16: 415-421.
29. Guo L, Abrams RM, Babiarz JE, et al. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci 2011; 123: 281-289.
30. Guo L, Qian JY, Abrams R, et al. The electrophysiological effects of cardiac glycosides in human ipsc-derived cardiomyocytes and in guinea pig isolated hearts. Cellular Physiol Biochem: Int J Exp Cell Physiol Biochem Pharmacol 2011; 27: 453-462.
31. Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovas Electrophysiol 2004; 15: 475-495.
32. Fermini B, Fossa AA,. The impact of drug-induced qt interval prolongation on drug discovery and development. Nat Rev. Drug Discov 2003; 2: 439-447.
33. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for qt prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European society of cardiology. Cardiovas Res 2000; 47: 219-233.
34. Giorgi MA, Bolanos R, Gonzalez CD, et al. Qt interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications. Curr Drug Saf 2010; 5: 54-57.
35. Yokoo N, Baba S, Kaichi S, et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun 2009; 387: 482-488.
36. Zeevi-Levin N, Itskovitz-Eldor J, Binah O,. Cardiomyocytes derived from human pluripotent stem cells for drug screening. Pharmacol Therapeut 2012; 134: 180-188.
37. Dick E, Rajamohan D, Ronksley J, et al. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. Biochem Soc Trans 2010; 38: 1037-1045.
38. Passier R, van Laake LW, Mummery CL,. Stem-cell-based therapy and lessons from the heart. Nature 2008; 453: 322-329.
39. Ebert AD, Svendsen CN,. Human stem cells and drug screening: opportunities and challenges. Nature reviews. Drug Discov 2010; 9: 367-372.
40. Patterson M, Chan DN, Ha I, et al. Defining the nature of human pluripotent stem cell progeny. Cell Res 2012; 22: 178-193.
41. Ma J, Guo L, Fiene SJ, et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am j physiol. Heart Circ Physiol 2011; 301: H2006-H2017.
42. Jonsson MK, Vos MA, Mirams GR, et al. Application of human stem cell-derived cardiomyocytes in safety pharmacology requires caution beyond herg. J Mol Cell Cardiol 2012; 52: 998-1008.
43. Honda M, Kiyokawa J, Tabo M, et al. Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells. J Pharmacol Sci 2011; 117: 149-159.
44. Fagiolini A, Comandini A, Catena Dell'Osso M, et al. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 2012; 26: 1033-1049.
45. DeVane CL, Boulton DW, Miller LF, et al. Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. Int J Neuropsychopharmacol 1999; 2: 17-23.
46. Otani K, Mihara K, Yasui N, et al. Plasma concentrations of trazodone and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone. Prog Neuro-Psychopharmacol Biol Psychiatry 1997; 21: 239-244.